2225109-03-3

2225109-03-3 structure

Name: Tafolecimab
Chemical Name: Tafolecimab
CAS Number: 2225109-03-3
Molecular Formula:
Molecular Weight:
Catalog: Signaling Pathways Metabolic Enzyme/Protease Ser/Thr Protease
Create Date: 2023-04-07 02:10:47
Modify Date: 2024-04-03 07:30:56
Tafolecimab (IBI-306) is a human lgG2 monoclonal antibody that specifically binds PCSK-9 and reduces LDL-C levels by inhibiting PCSK-9-mediated endocytosis of the LDL receptor, which in turn enhances clearance of LDL-C and leads to a reduction in LDL-C levels. Tafolecimab may be used in studies of hypercholesterolaemia[1].

Name	Tafolecimab

Description	Tafolecimab (IBI-306) is a human lgG2 monoclonal antibody that specifically binds PCSK-9 and reduces LDL-C levels by inhibiting PCSK-9-mediated endocytosis of the LDL receptor, which in turn enhances clearance of LDL-C and leads to a reduction in LDL-C levels. Tafolecimab may be used in studies of hypercholesterolaemia[1].
Related Catalog	Signaling Pathways >> Metabolic Enzyme/Protease >> Ser/Thr Protease Research Areas >> Cardiovascular Disease
References	[1]. Y Cui, et al. Tafolecimab, a novel potential long-acting PCSK9 monoclonal antibody: efficacy and safety in healthy and hypercholesterolemia subjects .European Heart Journal, Volume 41, Issue Supplement_2, November 2020.

No Any Chemical & Physical Properties